Showing results (41-50 of 253) with videos related to

Sort By:
Pageof 26
Hematological Oncology|September 23, 2025
A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and SelectionMonia Marchetti, Paolo Corradini, Luca Arcaini, et al.
Leukemia & Lymphoma|May 3, 2018
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survivalFrancesco Spina, Tommaso Radice, Chiara De Philippis, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
Leukemia & Lymphoma|July 24, 2018
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatmentMartina Pennisi, Luigi Berchicci, Elisabetta Miserocchi, et al.
Haematologica|December 18, 2023
Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <I>ad hoc</I> Italian expert panelCorrado Girmenia, Fabio Ciceri, Paolo Corradini, et al.
Annals of Hematology|April 6, 2012
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myelomaGiovanni Barosi, Giampaolo Merlini, Atto Billio, et al.
Haematologica|April 21, 2009
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantationLucia Farina, Cristiana Carniti, Anna Dodero, et al.
Leukemia & Lymphoma|November 21, 2008
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonatesVittorio Montefusco, Francesca Gay, Francesco Spina, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2015
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patientsPier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, et al.
Experimental Hematology|July 26, 2005
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayedAnna Dodero, Matteo Carrabba, Raffaella Milani, et al.
Pageof 26